A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of Nalbuphine Extended-Release Tablets for the Treatment of Participants with Refractory Chronic Cough
Placebo to match Nalbuphine erNalbuphine ERNalbuphine ER
Eligibility
Age group
65+ years, 18-64 years
Sex
Female, Male
Primary endpoint
Relative change from baseline in 24-hour cough frequency at Week 6 for each dose of NAL ER compared with placebo.
Endpoint detail
Relative change from baseline in 24-hour cough frequency at prespecified timepoints for NAL ER compared with placebo.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.